Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 in Acute Schizophrenia
CTR20213353Phase 3Terminated
- Sponsor
- Sunovion
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ulotaront in schizophrenia, sponsored by Sunovion. Started Dec 2021; status: terminated.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20213353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213353.